Multiple drugsWithdrawal symptoms and lack of efficacy: case report A male neonate [age not stated] developed withdrawal symptoms following in-utero exposure to quetiapine, gabapentin and lorazepam. He also exhibited lack of efficacy during treatment with hydrocortisone, nitric oxide, iloprost, sildenafil, epinephrine, norepinephrine and vasopressin in treatment of pulmonary hypertension [dosages not stated] [not all routes stated] [parent routes of administration not stated].The mother, who was primipara, presented to the hospital with acute respiratory distress syndrome (ARDS) caused by influenza-A-induced pneumonia, at 16 +5 gestational weeks. Due to irreversible lung damage, she underwent bilateral lung transplantation. Following transplantation, she started receiving immunosuppressive treatment with alemtuzumab, tacrolimus and unspecified steroids. She also received sedative and analgesic medications, which included quetiapine, gabapentin and lorazepam. Her posttransplant recovery was uneventful. On post-operative day 88, at 29 +3 gestational weeks, a Doppler scan of the umbilical artery showed zero flow with intermittent reverse flow. She was elected for a caesarean section. At 29 +5 gestational weeks, she was administered magnesium sulfate for fetal neuroprotection. A male neonate was delivered via caesarean section with an Apgar scores at 1, 5 and 10 min of 8, 9, and 9 and weight of 800g. After birth, he was transferred to the neonatal ICU. He had severe ARDS and received cardiorespiratory support by nasal continuous positive airway pressure (CPAP). After 25min of life, less invasive surfactant administration was performed. Subsequently, he developed withdrawal symptoms due to in-utero exposure to high levels of quetiapine, gabapentin and lorazepam. This resulted in the need of sedatives after birth. He was intubated and mechanically ventilated. He started receiving hydrocortisone for decreasing blood pressure. Echocardiography showed pulmonary hypertension. He started receiving inhaled nitric oxide, iloprost and sildenafil for pulmonary hypertension. He also started receiving norepinephrine [noradrenalin], epinephrine [adrenalin] and vasopressin for 2 days for arterial hypotension. He received thrombocyte concentrates for severe thrombocytopenia. However, he suffered from frequent, severe hypoxic events and pulmonary hypertension episodes (lack of efficacy). On postpartum day 5, despite the intensive care approach, the neonate died. Autopsy was performed and post-mortem histological examination confirmed persistent pulmonary hypertension as the cause of death [not all durations of treatments to reaction onset stated].